Financial Analysis: China SXT Pharmaceuticals (NASDAQ:SXTC) versus Cumberland Pharmaceuticals (NASDAQ:CPIX)

2026-04-03 08:12:44 ET

China SXT Pharmaceuticals ( NASDAQ:SXTC – Get Free Report ) and Cumberland Pharmaceuticals ( NASDAQ:CPIX – Get Free Report ) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership.

Profitability

This table compares China SXT Pharmaceuticals and Cumberland Pharmaceuticals’ net margins, return on equity and return on assets.

Earnings and Valuation

This table compares China SXT Pharmaceuticals and Cumberland Pharmaceuticals”s revenue, earnings per share and valuation.

Cumberland Pharmaceuticals has higher revenue and earnings than China SXT Pharmaceuticals.

Risk & Volatility

China SXT Pharmaceuticals has a beta of 1.75, meaning that its stock price is 75% more volatile than the S&P 500. Comparatively, Cumberland Pharmaceuticals has a beta of -0.33, meaning that its stock price is 133% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for China SXT Pharmaceuticals and Cumberland Pharmaceuticals, as reported by MarketBeat.

Insider & Institutional Ownership

5.0% of China SXT Pharmaceuticals shares are held by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. 4.0% of China SXT Pharmaceuticals shares are held by insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Cumberland Pharmaceuticals beats China SXT Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

About China SXT Pharmaceuticals

( Get Free Report )

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

About Cumberland Pharmaceuticals

( Get Free Report )

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.